Annals of Internal Medicine: Effects of Lamivudine on Replication of Hepatitis B Virus in HIV-Infected Men

Annals of Internal Medicine

Volumn 125, Issue 9, 1996, Pages 705-712

  Benhamou, Yves ^a   Katlama, Christine ^a   Lunel, Françoise ^a   Coutellier, Anne ^a   Dohin, Elisabeth ^a   Hamm, Nathalie ^a   Tubiana, Roland ^a   Herson, Serge ^a   Poynard, Thierry ^a   Opolon, Pierre ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA;

ADULT; AIDS RELATED COMPLEX; ARTICLE; BLOOD; DRUG EFFECT; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; PHYSIOLOGY; RETROSPECTIVE STUDY; VIRUS REPLICATION;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION;

EID: 0030292472     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-125-9-199611010-00001     Document Type: Article

References (31)

1. Kane MA. Progress on the control of hepatitis B infection through immunisation. Gut. 1993;34(2 Suppl):S10-2.
2. Rustgi VK, Hoofnagle JH, Gerin JL, Gelmann EP, Reichert CM, Cooper JN, et al. Hepatitis B virus infection in the acquired immunodeficiency syndrome. Ann Intern Med. 1984;101:795-7.
3. Weissberg JI, Andres LL, Smith CI, Weick S, Nichols JE, Garcia G, et al. Survival in chronic hepatitis B. An analysis of 379 patients. Ann Intern Med. 1984;101:613-6.
4. de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology. 1992;103:1630-5.
5. Taylor PE, Stevens CE, DeCordoba SR, Rubinstein P. Hepatitis 6 virus and human immunodeficiency virus: possible interactions. In: Zuckerman AJ, ed. Viral Hepatitis and Liver Disease: Proceedings of the International Symposium on Viral Hepatitis and Liver Disease, held at the Barbican Centre, London, May 26-28, 1987. New York: AR Liss; 1988:198-200.
6. Monno L, Angarano C, Lo Caputo S, Casalino C, Carbonara S, Santantonio T, et al. Unfavourable outcome of acute hepatitis B in anti-HIV positive drug addicts. In: Zuckerman AJ, ed. Viral Hepatitis and Liver Disease: Proceedings of the International Symposium on Viral Hepatitis and Liver Disease, held at the Barbican Centre, London, May 26-28, 1987. New York: AR Liss; 1988: 205-6.
7. Perrillo RP, Regenstein FG, Roodman ST. Chronic hepatitis B in asymptomatic homosexual men with antibody to the human immunodeficiency virus. Ann Intern Med. 1986;105:382-3.
8. Dianzani F. Biological basis for the clinical use of interferon. Gut. 1993;34(2 Suppl):S74-6.
9. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993;119:312-23.
10. McDonald JA, Caruso L, Karayiannis P, Scully LJ, Harris JR, Forster GE, et al. Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant alpha-interferon Hepatology. 1987;7:719-23.
11. Wong DK, Yim C, Naylor CD, Chen E, Sherman M, Vas S, et al. Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population. Gastroenterology. 1996; 108:165-71.
12. Lemp GF, Payne SF, Neal D, Temelso T, Rutherford GW. Survival trends for patients with AIDS. JAMA 1990;263:402-6.
13. Coates JA, Cammack N, Jenkinson HJ. The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob Agents Chemother. 1992;36:202-5.
14. van Leeuwen R, Katlama C, Kitchen V, Boucher CA, Tubiana R, McBride M, et al. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J Infect Dis. 1995;171:1166-71.
15. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci U S A. 1991;88:8495-9.
16. Tyrrell DL, Fischer K, Savani K, Tan W, Jewell L. Treatment of chimpanzees and ducks hepatitis with lamivudine, 2′,3′dideoxy 3′thiacytidine, results in a rapid suppression of hepaviral DNA in sera. Clin Invest Med. 1993; 16(Suppl 4):B77.
17. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. Preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 1995;333:1657-61.
18. Garcia F Jr, Garcia F, Bernal MC, Leyva A, Piedrola G, Maroto MC. Evaluation of enzyme immunoassay for hepatitis B virus DNA based on anti-double-stranded DNA. J Clin Microbiol. 1995;33:431-5.
19. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992;41(RR-17):1-19.
20. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1: 431-5.
21. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology. 1989;10:761-3.
22. Chang CN, Skalski V, Zhou JH, Cheng YC. Biochemical pharmacology of (+)- and (-)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents J Biol Chem. 1992;267:22414-20.
23. Ashman C, Larkin D, Cammack N, Boehme RE, Cameron JM. Lamivudine inhibits hepatitis B virus (HBV) production in the HBV transfected cell line 2.2.15 [Abstract]. Sixth International Symposium on Viral Hepatitis. Madrid: International Symposium on Viral Hepatitis; 1994:65.
24. Marcellin P, Ouzan D, Brechot C, Metman EH, Degott C, Chevalier M, et al. Randomized controlled trial of adenine arabinoside 5′-monophosphate in chronic active hepatitis B: comparison of the efficacy in heterosexual and homosexual patients. Hepatology. 1989;10:328-31.
25. Fried MW, Di Bisceglie AM, Strauss SE, Savarese B, Beames MP, Hoofnagle JH. FIAU, a new oral anti-viral agent, profoundly inhibits HBV DNA in patients with chronic hepatitis B [Abstract]. Hepatology. 1992;20: A209.
26. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med. 1995;333:1099-105.
27. Marcellin P, Pialoux G, Giarard PM, Boyer N, Martinot-Peignoux M, Loriot MA, et al. Absence of effect of zidovudine on replication of hepatitis B virus in patients with chronic HIV and HBV infection [Letter]. N Engl J Med. 1989;321:1758.
28. Antinori S, Esposito R, d'Arminio Monforte A, Moroni M. Foscarnet treatment of chronic hepatitis B in an HIV-positive patient [Letter]. J Hepatol. 1993;18:255-6.
29. Chossegros P, Pouteil-Noble C, Samuel D, Causse X, Ouzan D, Bizollon T, et al. Ganciclovir is an effective antiviral agent for post-transplantation chronic HBV infections, maintenance therapy may be required in some cases [Abstract]. Gastroenterology. 1993;104:A888.
30. Krogsgaard K, Lindhardt BO, Nielson JO, Andersson P, Kryger P, Aldershvile J, et al. The influence of HTLV-III infection on the natural history of hepatitis B virus infection in male homosexual HB5Ag carriers Hepatology. 1987;7:37-41.
31. Brook MG, Petrovic L, MacDonald JA, Scheuer PJ, Thomas HC. Evidence of histological improvement following antiviral treatment chronic hepatitis B virus carriers and identification of histological features that predict response. In: Zuckerman AJ, ed. Viral Hepatitis and Liver Disease: Proceedings of the International Symposium on Viral Hepatitis and Liver Disease, held at the Barbican Centre, London, May 26-28, 1987. New York: AR Liss; 1988:906-8.